{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:24:47Z","timestamp":1790112287282,"version":"4.0.1"},"reference-count":26,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,7,6]],"date-time":"2018-07-06T00:00:00Z","timestamp":1530835200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Arrhythmia"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>ROCKET AF and its East Asian subanalysis demonstrated that rivaroxaban was non\u2010inferior to warfarin for stroke\/systemic embolism (SE) prevention in patients with non\u2010valvular atrial fibrillation (NVAF), with a favorable benefit\u2013risk profile. XANAP investigated the safety and effectiveness of rivaroxaban in routine care in Asia\u2010Pacific.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>XANAP was a prospective, real\u2010world, observational study in patients with NVAF newly starting rivaroxaban. Patients were followed at ~3\u2010month intervals for 1 year, or for \u226530 days after permanent discontinuation. Primary outcomes were major bleeding events, adverse events (AEs), serious AEs and all\u2010cause mortality; secondary outcomes included stroke\/SE. Major outcomes were adjudicated centrally.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>XANAP enrolled 2273 patients from 10 countries: mean age was 70.5 years and 58.1% were male. 49.8% of patients received rivaroxaban 20 mg once daily (od), 43.8% 15 mg od and 5.9% 10 mg od. Mean treatment duration was 296 days, and 72.8% of patients had received prior anticoagulation therapy. Co\u2010morbidities included heart failure (20.1%), hypertension (73.6%), diabetes mellitus (26.6%), prior stroke\/non\u2010central nervous system SE\/transient ischemic attack (32.8%) and myocardial infarction (3.8%). Mean CHADS<jats:sub>2<\/jats:sub>, CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>\u2010VASc and HAS\u2010BLED scores were 2.3, 3.7 and 2.1, respectively. The rates (events\/100 patient\u2010years [95% confidence interval]) of treatment\u2010emergent major bleeding, stroke and all\u2010cause mortality were 1.5 (1.0\u20102.1), 1.7 (1.2\u20102.5) and 2.0 (1.4\u20102.7), respectively. Persistence was 66.2% at the study end.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The real\u2010world XANAP study demonstrated low rates of stroke and bleeding in rivaroxaban\u2010treated patients with NVAF from Asia\u2010Pacific. The results were consistent with the real\u2010world XANTUS study and ROCKET AF.<\/jats:p><\/jats:sec>","DOI":"10.1002\/joa3.12073","type":"journal-article","created":{"date-parts":[[2018,7,6]],"date-time":"2018-07-06T11:27:50Z","timestamp":1530876470000},"page":"418-427","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["XANAP: A real\u2010world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Asia"],"prefix":"10.1002","volume":"34","author":[{"given":"Young\u2010Hoon","family":"Kim","sequence":"first","affiliation":[{"name":"Korea University Medical Centre Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaemin","family":"Shim","sequence":"additional","affiliation":[{"name":"Korea University Medical Centre Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia\u2010Ti","family":"Tsai","sequence":"additional","affiliation":[{"name":"National Taiwan University Hospital Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun\u2010Chieh","family":"Wang","sequence":"additional","affiliation":[{"name":"Chang Gung Memorial Hospital Chang Gung University Taoyuan Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Vilela","sequence":"additional","affiliation":[{"name":"Philippine Heart Center Quezon City Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sombat","family":"Muengtaweepongsa","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Stroke Excellence Center Thammasat University Pathum Thani Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Kurniawan","sequence":"additional","affiliation":[{"name":"Department of Neurology Faculty of Medicine Cipto Mangunkusumo National Hospital Universitas Indonesia Jakarta Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oteh","family":"Maskon","sequence":"additional","affiliation":[{"name":"Department of Medicine National University of Malaysia Medical Centre (UKMMC) Kuala Lumpur Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsu","family":"Li Fern","sequence":"additional","affiliation":[{"name":"Novena Heart Centre Mount Elizabeth Novena Specialist Centre Singapore City Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thang Huy","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Neurology Department Pham Ngoc Thach Medical University Ho Chi Minh City Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thititat","family":"Thanachartwet","sequence":"additional","affiliation":[{"name":"Bayer (South East Asia) Pte Ltd Singapore City Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Sim","sequence":"additional","affiliation":[{"name":"Bayer (South East Asia) Pte Ltd Singapore City Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. John","family":"Camm","sequence":"additional","affiliation":[{"name":"Cardiology Clinical Academic Group St. George's University of London and Imperial College London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the XANAP investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,7,6]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euv231"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2014.22"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.113.002968"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-12-0454"},{"key":"e_1_2_8_9_1","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.joa.2013.03.002","article-title":"The APHRS's 2013 statement on antithrombotic therapy of patients with nonvalvular atrial fibrillation","volume":"29","author":"Ogawa S","year":"2014","journal-title":"J Arrhythm"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv466"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S63298"},{"key":"e_1_2_8_12_1","unstructured":"Bayer Pharma AG.Xarelto\u00ae(rivaroxaban) TAIWAN \u2010 summary of product characteristics. 2016. Available fromhttp:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025129&Seq=010&Type=9. Accessed March 23 2017."},{"key":"e_1_2_8_13_1","unstructured":"BayerAG.Xarelto\u00ae(rivaroxaban) summary of product characteristics. 2017. Available fromhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000944\/WC500057108.pdf. Accessed December 6 2017."},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157769"},{"key":"e_1_2_8_15_1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1590\/S1020-49892003000800013","article-title":"Poor adherence to long\u2010term treatment of chronic diseases is a worldwide problem. 2003","volume":"14","year":"2003","journal-title":"Rev Panam Salud Publica"},{"key":"e_1_2_8_16_1","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.thromres.2017.04.010","article-title":"Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: a subgroup analysis from the ROCKET AF trial","volume":"156","author":"Sun Y","year":"2017","journal-title":"Thromb Res"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1159\/000437109"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151743"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.108.535724"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.018820"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31829bfde3"},{"key":"e_1_2_8_22_1","unstructured":"HoriM.The safety and efficacy of rivaroxaban for prevention of stroke in Japanese patients with non\u2010valvular atrial fibrillation. XXIII Congress of The International Society on Thrombosis and Haemostasis. Kyoto Japan 23\u201328 July 2011 Oral presentation."},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j510"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.06.062"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.09.024"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr342"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu305"}],"container-title":["Journal of Arrhythmia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjoa3.12073","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/joa3.12073","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/joa3.12073","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/joa3.12073","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T15:35:09Z","timestamp":1693841709000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/joa3.12073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,6]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1002\/joa3.12073"],"URL":"https:\/\/doi.org\/10.1002\/joa3.12073","archive":["Portico"],"relation":{},"ISSN":["1880-4276","1883-2148"],"issn-type":[{"value":"1880-4276","type":"print"},{"value":"1883-2148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,6]]},"assertion":[{"value":"2017-11-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}